TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiabetes Mellitus, Type 2Impaired Glucose Tolerance (IGT)Impaired Fasting Glucose (IFG)

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

Sponsor: The University of Texas Health Science Center at San Antonio

You may qualify if…

  • NGT subjects will serve as controls and will be matched in age, gender, ethnicity, and BMI to IGT and IFG subjects
  • 1. Male or female subjects between the ages of 18 and 65 years of age, inclusive, at Screening.
  • 2. FPG \< 100 mg/dl and 2-h PG \< 140 mg/dl
  • 3. BMI = 24-40 kg/m2;
  • 4. Stable body weight (±4lbs) over the preceding 3 months
  • 5. Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data
  • 6. Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose):
  • Oral contraceptive

You may not qualify if…

  • 1. Recent (i.e., within three (3) months prior to Screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological, or clinically significant neurological disease.
  • 2. Subjects with a family history of diabetes in a first degree relative
  • 3. BMI of less than 24 or greater than 40 kg/m2
  • 4. Unstable body weight (change of greater than ±4lbs over the preceding 3 months
  • 5. Subjects participating in an excessively heavy exercise program
  • 6. Subject with a feeding/sleeping schedule different from a daytime feeding/night time sleeping schedule
  • 7. Subjects taking medications known to alter glucose metabolism (with the exception of metformin and/or pioglitazone) or which effect brain neurosynaptic function are excluded.
  • 8. Subjects with evidence of major organ system disease as determined by physical exam, history, and screening laboratory data

Where it's recruiting

Texas

San Antonio

Source: ClinicalTrials.gov · NCT02969798 · last updated 2025-08-27

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impair · TrialPath